The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility-Reference-Cited by-同舟云学术

The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility

Published:2023-12 Issue: Volume:192 Page:104148
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Antonarelli Gabriele^ORCID,Taurelli Salimbeni Beatrice,Marra Antonio,Esposito Angela,Locatelli Marzia Adelia,Trapani Dario,Pescia Carlo,Fusco Nicola,Curigliano Giuseppe,Criscitiello Carmen

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference149 articles.

1. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast cancer therapy expert group (BCTEG);Abraham;Breast Cancer Res. Treat.,2018

2. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer;Al-Qasem;NPJ Precis. Oncol.,2022

3. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials;Andre;JCO,2020

4. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials;Andre;Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.,2023

5. CDK4/6 inhibitor biomarker research: are we barking up the wrong tree?;Anurag;Clin. Cancer Res,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer;Cancer Letters;2024-07

2. Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer;International Journal of Molecular Sciences;2024-03-15

3. Aberrant cytoplasmic localization of MLH1 characterizes a sub-clonal breast cancer cell population that seeds recurrence;2024-03-02